The aims of this comparison were (a) to establish whether more or fewer patients would be in the "grey area" of diagnosis and (b) to monitor and estimate any difference in the percentage increases in CEA, depending on the method used. On comparing the two methods, we found that the in-house method produced "grey area" results in 31 patients with colorectal cancer, compared with only 19 patients with the Abbott assay ( Figure la) . Therefore, we found a greater number of patients with unequivocally increased values if we used the Abbott assay instead of the inhouse assay-which may indicate that the monoclonal kit could be a more sensitive indicator of disease. In other forms of cancer, we found no difference in the number of unequivocally in-
We compared the Abbott CEA RIA, 2.
a monoclonal-antibody-based assay, ic,
with an in-house radioimmunoassay, using samples from 53 patients (mean age 66 y, range 37 to 88 y) with clinically and histologically confirmed cobrectal carcinoma and 12 patients (mean age 55 y, range 29 to 73 y) with other forms of cancer (nine gastric, two breast, and one ovarian). The in-house method was a double-antibody technique based upon a previously described method (2). We used only patients' sera with increased in-house CEA values >30 g/L (in-house reference interval: <15 pg/L). The CEA values determined by the in-house method are different from usually quoted figures, because these figures were assigned before an international reference standard became available.
Increased CEA values can also be seen in smokers, and in patients with liver diseases, ulcerative colitis, and several other disorders. However, CEA values exceeding five times the upper limit of normal are usually only seen in cancers of the gastrointestinal tract. For the in-house assay this would be >75 ,u.g/L, and for the Abbott assay (reference interval:
The aims of this comparison were (a) to establish whether more or fewer patients would be in the "grey area" of diagnosis and (b) to monitor and estimate any difference in the percentage increases in CEA, depending on the method used. 
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On comparing the two methods, we found that the in-house method produced "grey area" results in 31 patients with colorectal cancer, compared with only 19 patients with the Abbott assay (Figure la) . Therefore, we found a greater number of patients with unequivocally increased values if we used the Abbott assay instead of the inhouse assay-which may indicate that the monoclonal kit could be a more sensitive indicator of disease. In other forms of cancer, we found no difference in the number of unequivocally in- possibly because of a lower background nonspecificity with the monoclonal kit. This may mean that more dramatic changes in CEA will be seen when cases are followed up.
Possibly the broader specificity of a polyclonal assay could give rise to a i.e., were "grey area" results. Thus, any diagnostic potential of using a polyclonal assay would be offset by the uncertainty in interpreting slightly increased CEA values. We are currently collecting further data that support this idea, evaluating more than 800 patients in whom we have measured CEA by a polyclonal method and the Hybritech monocbonal assay. Only one patient has shown significantly increased CEA values (i.e., more than fivefold the upper reference limit) by the polyclonal assay and a normal value by the monoclonal assay.
